10:37 AM EDT, 05/06/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) expects it will not see generic versions of its diabetes drug Ozempic in China until at least April 2027, Bloomberg News reported Wednesday, citing an emailed statement from the Danish drugmaker.

While the patent for semaglutide, the active ingredient in Novo Nordisk's blockbusters Ozempic and Wegovy, expired in China in March, Ozempic still retains regulatory data protection under a trade deal between China and Switzerland, the company reportedly said. Novo Nordisk's Swiss unit holds the market authorization for the drug in China.

Novo Nordisk ADR

Senast

46,06

1 dag %

2,65%

1 dag

1 mån

1 år

Novo Nordisk B

Senast

293,00

1 dag %

2,48%
Marknadsöversikt

1 DAG %

Senast

1 mån